57962-45-5

Usage

Uses

Used in Pharmaceutical Industry:
4-Benzyl-2-morpholineacetonitrile is used as a key intermediate in the production of different types of medications, including antihistamines and antitumor drugs. Its presence in these medications is attributed to its pharmacological properties, which contribute to their therapeutic effects.
Used in Organic Synthesis:
This chemical compound also serves as a building block in organic synthesis, where it is utilized to create various functionalized molecules. Its versatility in chemical reactions allows for the development of a wide range of organic compounds for various applications.

InChI:InChI=1/C13H16N2O/c14-7-6-13-11-15(8-9-16-13)10-12-4-2-1-3-5-12/h1-5,13H,6,8-11H2

Upstream product

• 40987-25-5 N-benzyl-2-chloromethylmorpholine 
• 151-50-8 potassium cyanide 
• 773837-37-9 sodium cyanide 
• 58040-32-7 2-(4-benzyl-morpholin-2-yl)-1-phenyl-ethanone 
• 40987-53-9 4-benzyl-2-(toluene-p-sulphonyloxymethyl)morpholine 
• 104-63-2 N-Benzylethanolamine 

Downstream Products

• 112914-08-6 2-(2-aminoethyl)-4-benzylmorpholine 
• 135072-27-4 4-benzyl-2-(carbamoylmethyl)morpholine 
• 146944-29-8 4-benzyl-2-(((ethoxycarbonyl)amino)methyl)morpholine 
• 654682-01-6 4-benzyl-2-phenacylmorpholine hydrochloride 
• 146944-27-6 4-benzylmorpholine-2-acetic acid 
• 766539-34-8 methyl 2-(4-benzylmorpholine-2-yl)acetate 

Relevant academic research and scientific papers

A COMPOUND FOR INHIBITING HUMAN 11-β-HYDROXY STEROID DEHYDROGENASE TYPE 1, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

The present invention relates to a novel compound, or a stereoisomer, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition for human-11-beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) comprising the same. The invention provides a compound, which has excellent activity and solubility and is more efficiently formulated and delivered, and a pharmaceutical composition for human-11-beta-hydroxysteroid dehydrogenase type 1 comprising the same.

Novel benzamides as selective and potent gastric prokinetic agents. 1. Synthesis and structure-activity relationships of N-[(2-morpholinyl)alkyl]benzamides

With the purpose of obtaining more potent and selective gastric prokinetic agents than metoclopramide (1), a new series of N-[(2-morpholinyl)alkyl]benzamides (17-52) were synthesized and their gastric prokinetic activity was evaluated by determining effect on the gastric emptying of phenol red semisolid meal and of resin pellets solid meal in rats and mice. The morpholinyl moiety was newly designed after consideration of the side-chain structure of cisapride (2) and produced the desired activity when coupled with the 4-amino-5-chloro-2-methoxybenzoyl group of both metoclopramide and cisapride. Modification of the substituents of the benzoyl group markedly influenced the activity. In particular, 4-amino-N-[benzyl-2-morpholinyl)methyl]-5-chloro-2-methoxybenzamide (17) and the 4-(dimethylamino) and 2-ethoxy analogues (25 and 29) or 17 showed potent and selective gastric prokinetic activity along with a weak dopamine D2 receptor antagonistic activity.

Substituted benzamide derivatives, for enhancing gastrointestinal motility

Compounds of the formula: STR1 wherein R is hydrogen, alkoxycarbonyl, benzyloxycarbonyl, heteroarylalkyl, phenylalkenyl, or --T--(Y)p --R6 (wherein T is single bond or alkylene, Y is oxygen, sulfur or carbonyl, R6 is phenyl, substituted phenyl, naphthyl, or diphenylmethyl, and p is 0 or 1, provided that when T is single bond, p is 0); R1 is halogen, hydroxy, alkoxy, cycloalkyloxy, alkenyloxy, alkynyloxy, alkoxy interrupted by oxygen or carbonyl, alkylthio, amino, monosubstituted amino, or a substituted alkoxy; R2 is hydrogen; R3 is hydrogen, halogen, amino, alkylamino, dialkylamino, alkanoylamino, or nitro; R4 is hydrogen, halogen, nitro, sulfamoyl, alkylsulfamoyl, or dialkylsulfamoyl; or any two adjacent groups of the R1, R2, R3 and R4 may combine to form alkylenedioxy, and the remaining two groups are each hydrogen; R5 is hydrogen or alkyl; X is alkylene; m and n are each 1 or 2; provided that at least one of the groups R2, R3 and R4 is other than hydrogen, and acid addition salts, quaternary ammonium salts and N-oxide derivatives thereof, processes for preparation thereof, and pharmaceutical composition containing the same. Said compounds, salts and N-oxide derivatives thereof show excellent gastrointestinal motility enhancing activity.

Phenylvinyl morpholine compounds

Morpholine derivatives, typically those of the formula: STR1 wherein A is an ethylene or vinylene radical and X is a phenyl radical optionally substituted by one or two substituents selected from halogen atoms, alkyl and alkoxy radicals of 1 to 6 carbon a